Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Adverse events associated with weight-based, high-dose montelukast exposures in children.

Arnold DH, Bowman N, Reiss TF, Hartert TV, Akers WS, Seger DL.

Clin Toxicol (Phila). 2019 May 6:1-2. doi: 10.1080/15563650.2019.1609686. [Epub ahead of print] No abstract available.

PMID:
31056949
2.

Adverse events are rare after single-dose montelukast exposures in children.

Arnold DH, Bowman N, Reiss TF, Hartert TV, Seger DL.

Clin Toxicol (Phila). 2018 Jan;56(1):25-29. doi: 10.1080/15563650.2017.1337123. Epub 2017 Jun 22.

3.

An Official American Thoracic Society Research Statement: Implementation Science in Pulmonary, Critical Care, and Sleep Medicine.

Weiss CH, Krishnan JA, Au DH, Bender BG, Carson SS, Cattamanchi A, Cloutier MM, Cooke CR, Erickson K, George M, Gerald JK, Gerald LB, Goss CH, Gould MK, Hyzy R, Kahn JM, Mittman BS, Mosesón EM, Mularski RA, Parthasarathy S, Patel SR, Rand CS, Redeker NS, Reiss TF, Riekert KA, Rubenfeld GD, Tate JA, Wilson KC, Thomson CC; ATS Ad Hoc Committee on Implementation Science.

Am J Respir Crit Care Med. 2016 Oct 15;194(8):1015-1025.

4.

Predictors of asthma following severe respiratory syncytial virus (RSV) bronchiolitis in early childhood.

Lu S, Hartert TV, Everard ML, Giezek H, Nelsen L, Mehta A, Patel H, Knorr B, Reiss TF.

Pediatr Pulmonol. 2016 Dec;51(12):1382-1392. doi: 10.1002/ppul.23461. Epub 2016 May 6.

5.

BEAR Cage: Mentoring through Engagement.

Reiss TF, Moss J, Watkins TR, Malhotra A.

Am J Respir Crit Care Med. 2016 Apr 1;193(7):714-6. doi: 10.1164/rccm.201602-0297ED. No abstract available.

PMID:
26910761
6.

Drug development for airway diseases: looking forward.

Holgate S, Agusti A, Strieter RM, Anderson GP, Fogel R, Bel E, Martin TR, Reiss TF.

Nat Rev Drug Discov. 2015 Jun;14(6):367-8. doi: 10.1038/nrd4645. Epub 2015 May 22.

PMID:
26000726
7.

The asthma disease activity score: a discriminating, responsive measure predicts future asthma attacks.

Greenberg S, Liu N, Kaur A, Lakshminarayanan M, Zhou Y, Nelsen L, Gates DF Jr, Kuo WL, Smugar SS, Reiss TF, Barnes N, Fuhlbrigge A, Milgrom H, Schatz M, Knorr B.

J Allergy Clin Immunol. 2012 Nov;130(5):1071-1077.e10. doi: 10.1016/j.jaci.2012.07.057. Epub 2012 Oct 1.

PMID:
23036744
8.

Collaborative science and the American Thoracic Society: cooperation in harmony with conflict of interest.

Reiss TF, Moss J, Osborne M, Curtis JR, Hill NS.

Am J Respir Crit Care Med. 2012 Feb 15;185(4):347-9. doi: 10.1164/rccm.201110-1824ED. No abstract available.

9.

Airway obstruction lability helps distinguish levels of disease activity in asthma.

Greenberg S, Liu N, Kaur A, Lakshminarayanan M, Zhou Y, Nelsen LM, Smugar SS, Noonan G, Reiss TF, Knorr BA.

Respir Med. 2012 Apr;106(4):500-7. doi: 10.1016/j.rmed.2011.12.013. Epub 2012 Jan 31.

10.

The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma.

Wasfi YS, Villarán C, de Tilleghem Cle B, Smugar SS, Hanley WD, Reiss TF, Knorr BA.

Respir Med. 2012 Jan;106(1):34-46. doi: 10.1016/j.rmed.2011.08.019. Epub 2011 Sep 25.

11.

Intermittent or daily montelukast versus placebo for episodic asthma in children.

Valovirta E, Boza ML, Robertson CF, Verbruggen N, Smugar SS, Nelsen LM, Knorr BA, Reiss TF, Philip G, Gurner DM.

Ann Allergy Asthma Immunol. 2011 Jun;106(6):518-26. doi: 10.1016/j.anai.2011.01.017. Epub 2011 Mar 4.

PMID:
21624752
12.

The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma.

Philip G, Villarán C, Shah SR, Vandormael K, Smugar SS, Reiss TF.

J Asthma. 2011 Jun;48(5):495-502. doi: 10.3109/02770903.2011.573042. Epub 2011 May 5.

PMID:
21545249
13.

MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease.

Bernstein JA, Liu N, Knorr BA, Smugar SS, Hanley WD, Reiss TF, Greenberg S.

Respir Med. 2011 Mar;105(3):392-401. doi: 10.1016/j.rmed.2010.09.021. Epub 2010 Nov 13.

14.

A phase I randomized, placebo-controlled, dose-exploration study of single-dose inhaled montelukast in patients with chronic asthma.

Philip G, Pedinoff A, Vandormael K, Tymofyeyev Y, Smugar SS, Reiss TF, Korenblat PE.

J Asthma. 2010 Dec;47(10):1078-84. doi: 10.3109/02770903.2010.520100. Epub 2010 Nov 3.

PMID:
20936994
15.

A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma.

Camargo CA Jr, Gurner DM, Smithline HA, Chapela R, Fabbri LM, Green SA, Malice MP, Legrand C, Dass SB, Knorr BA, Reiss TF.

J Allergy Clin Immunol. 2010 Feb;125(2):374-80. doi: 10.1016/j.jaci.2009.11.015.

PMID:
20159247
16.

Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis.

Lu S, Malice MP, Dass SB, Reiss TF.

J Asthma. 2009 Nov;46(9):878-83. doi: 10.3109/02770900903104540.

PMID:
19905912
17.

Analysis of behavior-related adverse experiences in clinical trials of montelukast.

Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF, Knorr B.

J Allergy Clin Immunol. 2009 Oct;124(4):699-706.e8. doi: 10.1016/j.jaci.2009.08.011. Erratum in: J Allergy Clin Immunol. 2010 May;125(5):1019.

PMID:
19815116
18.

Reports of suicidality in clinical trials of montelukast.

Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, Knorr B.

J Allergy Clin Immunol. 2009 Oct;124(4):691-6.e6. doi: 10.1016/j.jaci.2009.08.010.

PMID:
19815114
19.

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis.

Philip G, van Adelsberg J, Loeys T, Liu N, Wong P, Lai E, Dass SB, Reiss TF.

J Allergy Clin Immunol. 2009 Nov;124(5):942-8.e1-9. doi: 10.1016/j.jaci.2009.07.006. Epub 2009 Sep 12.

PMID:
19748656
20.
21.

Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions.

Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, Knorr B, Noonan G.

Pediatr Pulmonol. 2009 Jun;44(6):568-79. doi: 10.1002/ppul.21018. Review.

PMID:
19449366
22.

Montelukast and bronchial inflammation in asthma: a randomised, double-blind placebo-controlled trial.

Ramsay CF, Sullivan P, Gizycki M, Wang D, Swern AS, Barnes NC, Reiss TF, Jeffery PK.

Respir Med. 2009 Jul;103(7):995-1003. doi: 10.1016/j.rmed.2009.01.019. Epub 2009 Feb 26.

23.

Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma.

Lu S, Liu N, Dass SB, Reiss TF, Knorr BA.

Respir Med. 2009 Mar;103(3):342-7. doi: 10.1016/j.rmed.2008.10.024. Epub 2009 Jan 8.

24.

Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children.

Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, Marchal JL, Dass SB, Reiss TF, Knorr BA.

Am J Respir Crit Care Med. 2008 Oct 15;178(8):854-60. doi: 10.1164/rccm.200706-910OC. Epub 2008 Jun 26.

PMID:
18583576
25.

Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis.

Kearns GL, Lu S, Maganti L, Li XS, Migoya E, Ahmed T, Knorr B, Reiss TF.

J Clin Pharmacol. 2008 Apr;48(4):502-11. doi: 10.1177/0091270008314251. Epub 2008 Feb 22.

PMID:
18296556
26.

Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children.

Pedersen S, Agertoft L, Williams-Herman D, Kuznetsova O, Reiss TF, Knorr B, Dass SB, Wolthers OD.

Pediatr Pulmonol. 2007 Sep;42(9):838-43.

PMID:
17659605
27.

Efficacy of montelukast for treating perennial allergic rhinitis.

Philip G, Williams-Herman D, Patel P, Weinstein SF, Alon A, Gilles L, Tozzi CA, Dass SB, Reiss TF.

Allergy Asthma Proc. 2007 May-Jun;28(3):296-304.

PMID:
17619558
28.

Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction.

Philip G, Pearlman DS, Villarán C, Legrand C, Loeys T, Langdon RB, Reiss TF.

Chest. 2007 Sep;132(3):875-83. Epub 2007 Jun 15.

PMID:
17573489
29.

Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast.

Philip G, Villarán C, Pearlman DS, Loeys T, Dass SB, Reiss TF.

J Asthma. 2007 Apr;44(3):213-7.

PMID:
17454341
30.

Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence.

Green SA, Alon A, Ianus J, McNaughton KS, Tozzi CA, Reiss TF.

J Urol. 2006 Dec;176(6 Pt 1):2535-40; discussion 2540.

PMID:
17085151
31.

Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast.

Pearlman DS, van Adelsberg J, Philip G, Tilles SA, Busse W, Hendeles L, Loeys T, Dass SB, Reiss TF.

Ann Allergy Asthma Immunol. 2006 Jul;97(1):98-104.

PMID:
16892789
32.

An oral selective M3 cholinergic receptor antagonist in COPD.

Lu S, Parekh DD, Kuznetsova O, Green SA, Tozzi CA, Reiss TF.

Eur Respir J. 2006 Oct;28(4):772-80. Epub 2006 Jul 26.

33.

Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study.

Becker AB, Kuznetsova O, Vermeulen J, Soto-Quiros ME, Young B, Reiss TF, Dass SB, Knorr BA; Pediatric Montelukast Linear Growth Study Group.

Ann Allergy Asthma Immunol. 2006 Jun;96(6):800-7.

PMID:
16802767
34.

Montelukast effectively treats the nighttime impact of seasonal allergic rhinitis.

Meltzer EO, Philip G, Weinstein SF, LaForce CF, Malice MP, Dass SB, Santanello NC, Reiss TF.

Am J Rhinol. 2005 Nov-Dec;19(6):591-8.

PMID:
16402647
35.

Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis.

Patel P, Philip G, Yang W, Call R, Horak F, LaForce C, Gilles L, Garrett GC, Dass SB, Knorr BA, Reiss TF.

Ann Allergy Asthma Immunol. 2005 Dec;95(6):551-7.

PMID:
16400895
36.

Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma.

van Adelsberg J, Moy J, Wei LX, Tozzi CA, Knorr B, Reiss TF.

Curr Med Res Opin. 2005 Jun;21(6):971-9.

PMID:
15969897
37.

Onset of efficacy of montelukast in seasonal allergic rhinitis.

Weinstein SF, Philip G, Hampel FC Jr, Malice MP, Swern AS, Dass SB, Reiss TF.

Allergy Asthma Proc. 2005 Jan-Feb;26(1):41-6.

PMID:
15813287
38.

Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure.

Perry TT, Corren J, Philip G, Kim EH, Conover-Walker MK, Malice MP, Massaad R, Dass SB, Reiss TF, Wood RA.

Ann Allergy Asthma Immunol. 2004 Nov;93(5):431-8.

PMID:
15562881
39.

The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis.

Philip G, Nayak AS, Berger WE, Leynadier F, Vrijens F, Dass SB, Reiss TF.

Curr Med Res Opin. 2004 Oct;20(10):1549-58.

PMID:
15462688
40.

Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies.

Chervinsky P, Philip G, Malice MP, Bardelas J, Nayak A, Marchal JL, van Adelsberg J, Bousquet J, Tozzi CA, Reiss TF.

Ann Allergy Asthma Immunol. 2004 Mar;92(3):367-73.

PMID:
15049402
41.

Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation.

Green SA, Malice MP, Tanaka W, Tozzi CA, Reiss TF.

Thorax. 2004 Feb;59(2):100-4.

42.

Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period.

van Adelsberg J, Philip G, Pedinoff AJ, Meltzer EO, Ratner PH, Menten J, Reiss TF; Montelukast Fall Rhinitis Study Group.

Allergy. 2003 Dec;58(12):1268-76. Erratum in: Allergy. 2004 Mar;59(3):357. Allergy. 2009 Nov;64(11):1697.

PMID:
14616102
43.

Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis.

van Adelsberg J, Philip G, LaForce CF, Weinstein SF, Menten J, Malice MP, Reiss TF; Montelukast Spring Rhinitis Investigator Group.

Ann Allergy Asthma Immunol. 2003 Feb;90(2):214-22.

PMID:
12602669
44.

Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone.

Baumgartner RA, Martinez G, Edelman JM, Rodriguez Gomez GG, Bernstein M, Bird S, Angner R, Polis A, Dass SB, Lu S, Reiss TF; Montelukast Asthma Study Group.

Eur Respir J. 2003 Jan;21(1):123-8.

45.

A randomized controlled trial of intravenous montelukast in acute asthma.

Camargo CA Jr, Smithline HA, Malice MP, Green SA, Reiss TF.

Am J Respir Crit Care Med. 2003 Feb 15;167(4):528-33. Epub 2002 Nov 27.

PMID:
12456380
46.

Variability and lack of predictive ability of asthma end-points in clinical trials.

Zhang J, Yu C, Holgate ST, Reiss TF.

Eur Respir J. 2002 Nov;20(5):1102-9.

47.

Safety of chewable tablets for children.

Michele TM, Knorr B, Vadas EB, Reiss TF.

J Asthma. 2002 Aug;39(5):391-403. Review.

PMID:
12214893
48.

Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring.

Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, Ratner PH, Malice MP, Reiss TF; Montelukast Spring Rhinitis Study Group.

Clin Exp Allergy. 2002 Jul;32(7):1020-8. Erratum in: Clin Exp Allergy. 2009 Oct;39(10):1622.

PMID:
12100048
49.

Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.

Nayak AS, Philip G, Lu S, Malice MP, Reiss TF; Montelukast Fall Rhinitis Investigator Group.

Ann Allergy Asthma Immunol. 2002 Jun;88(6):592-600.

PMID:
12086367
50.

Effect of montelukast, a once-daily leukotriene receptor antagonist, on peak expiratory flow variability.

Zhang J, Yu C, Noonan G, Reiss TF.

Clin Ther. 2002 Apr;24(4):574-82.

PMID:
12017402

Supplemental Content

Loading ...
Support Center